Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-301-5157260
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees192
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."
How were Senseonics' earnings last quarter?
Senseonics Holdings Inc (NYSEAMERICAN:SENS) issued its earnings results on Wednesday, August, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.01. The firm earned $4.61 million during the quarter, compared to analyst estimates of $4.52 million. View Senseonics' Earnings History.
When is Senseonics' next earnings date?
What guidance has Senseonics issued on next quarter's earnings?
Senseonics updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $25-30 million, compared to the consensus revenue estimate of $26.36 million.
What price target have analysts set for SENS?
4 brokers have issued 1 year price objectives for Senseonics' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Senseonics' stock price to reach $2.00 in the next year. This suggests a possible upside of 132.6% from the stock's current price. View Analyst Price Targets for Senseonics.
What is the consensus analysts' recommendation for Senseonics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Senseonics.
Has Senseonics been receiving favorable news coverage?
Press coverage about SENS stock has trended negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Senseonics earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Senseonics.
Are investors shorting Senseonics?
Senseonics saw a increase in short interest in September. As of September 30th, there was short interest totalling 38,320,000 shares, an increase of 5.7% from the August 30th total of 36,250,000 shares. Based on an average daily volume of 2,010,000 shares, the short-interest ratio is presently 19.1 days. Currently, 33.6% of the shares of the company are sold short. View Senseonics' Current Options Chain.
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Palatin Technologies (PTN), Renalytix Ai (RENX), Exagen (XGN), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), BARD1 Life Sciences (BD1), Oncimmune (ONC), Oncosil Medical (OSL), Sernova (SVA), Lexagene (LXG) and SQI Diagnostics (SQD).
What other stocks do shareholders of Senseonics own?
Who are Senseonics' key executives?
Senseonics' management team includes the folowing people:
- Dr. Timothy T. Goodnow, Pres, CEO & Director (Age 57)
- Dr. Mukul Jain, Chief Operating Officer (Age 46)
- Mr. Jon D. Isaacson, Chief Financial Officer
- Dr. Francine Ratner Kaufman, Chief Medical Officer
- Ms. Mirasol G. Panlilio, VP & Gen. Mang. of Global Commercial Operations (Age 54)
Who are Senseonics' major shareholders?
Senseonics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Canton Hathaway LLC (0.02%). Company insiders that own Senseonics stock include Douglas A Roeder, Mukul Jain, Peter J Barris and Timothy T Goodnow. View Institutional Ownership Trends for Senseonics.
Which institutional investors are selling Senseonics stock?
How do I buy shares of Senseonics?
Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Senseonics' stock price today?
One share of SENS stock can currently be purchased for approximately $0.86.
How big of a company is Senseonics?
What is Senseonics' official website?
How can I contact Senseonics?
Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.
MarketBeat Community Rating for Senseonics (NYSEAMERICAN SENS)
MarketBeat's community ratings are surveys of what our community members think about Senseonics and other stocks. Vote "Outperform" if you believe SENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
